Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Schweiger, M; Stiegler, P; Puntschart, A; Sereinigg, M; Prenner, G; Wasler, A; Tscheliessnigg, K.
Everolimus in different combinations as maintenance immunosuppressive therapy in heart transplant recipients.
Exp Clin Transplant. 2012; 10(3):273-277 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG


Autor/innen der Med Uni Graz:
Prenner Günther
Puntschart Andreas
Schweiger Martin
Sereinigg Michael
Stiegler Philipp
Tscheliessnigg Karlheinz
Wasler Andrä

Dimensions Citations:

Plum Analytics:
Objectives: We examined the experiences of heart transplant recipients receiving everolimus as maintenance therapy in different combinations over a long time. Materials and Methods: Between 2004 and 2009, forty patients (29 men, 11 women; mean age, 51.6 y) were switched from a routine immunosuppressive regimen to everolimus. Indications were other (2), renal insufficiency (17), cardiac allograft vasculopathy (14), and ongoing cellular rejection (7). Combinations were either along with cyclosporine (24), mycophenolate mofetil (14), or others (2). Indications for the introduction of everolimus including safety, efficacy, different combinations of everolimus, biopsy-proven acute rejections, renal function, and infections were evaluated retrospectively. Results: Five patients died, 4 of them were still on everolimus at the time of death; they died from intracerebral hemorrhage (1), embolism (1), cardiac arrest (2), and unknown (1). Everolimus was discontinued in 6 patients owing to severe adverse effects: Edema (2), gastrointestinal adverse effects (3), and dermal adverse effects (1). Mean everolimus trough levels were 5.8 mu mol/L at 6 months and 4.9 at 60 months. Mean cyclosporine levels were 67.62 mu mol/L at 6 months and 47.3 mu mol/L at 60 months. Mean serum creatinine levels were stable (147.9 mu mol/L after 60 months). Four life-threatening infections (all pneumonia) occurred but resulted in complete recovery. Conclusions: Everolimus is safe with different immunosuppressive combinations after receiving a heart transplant.
Find related publications in this database (using NLM MeSH Indexing)
Adult -
Aged -
Aged, 80 and over -
Biopsy -
Cyclosporine - therapeutic use
Drug Therapy, Combination -
Edema - chemically induced
Female -
Gastrointestinal Diseases - chemically induced
Graft Rejection - immunology
Heart Transplantation - immunology
Humans -
Immunosuppressive Agents - therapeutic use
Incidence -
Longitudinal Studies -
Male -
Middle Aged -
Mycophenolic Acid - analogs & derivatives
Retrospective Studies -
Sirolimus - adverse effects
Treatment Outcome -

Find related publications in this database (Keywords)
Renal failure
Proliferation inhibitors
Calcineurin inhibitor-free protocols
Midterm follow-up
© Med Uni Graz Impressum